Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.47 |
| ▸ | CA2 | P00918 | 4/20 | 0.47 |
| ▸ | CA12 | O43570 | 3/20 | 0.47 |
| ▸ | CA7 | P43166 | 3/20 | 0.47 |
| ▸ | CA9 | Q16790 | 3/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.47 |
| ▸ | XDH | P47989 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | MAPT | P10636 | 6/20 | 0.45 |
| ▸ | RAB9A | P51151 | 4/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6134999 | 0.81 | CA12 (0.51) | CA1CA2CA12CA7CA9 | |
| SCHEMBL971745 | 0.81 | CA12 (0.51) | CA1CA2CA12CA7CA9 | |
| SCHEMBL7165180 | 0.79 | CA1 (0.53) | CA1CA2CA12CA7CA9 | |
| SCHEMBL1100872 | 0.79 | CA1 (0.48) | CA1CA2CA12CA7CA9 | |
| SCHEMBL128693 | 0.79 | CA1 (0.48) | CA1CA2CA12CA7CA9 | |
| SCHEMBL561510 | 0.79 | NPC1 (0.38) | ALDH1A1MAPTRAB9ANPC1MEN1 | |
| SCHEMBL7988773 | 0.78 | ALDH1A1 (0.38) | ALDH1A1MAPTTSHRHPGDHSD17B10 | |
| SCHEMBL4286215 | 0.78 | CA1 (0.47) | CA1CA2CA12CA7CA9 | |
| SCHEMBL3728487 | 0.78 | KDM4E (0.51) | CA1CA2CA12CA7CA9 | |
| SCHEMBL3964444 | 0.78 | CA1 (0.47) | CA1CA2CA12CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102827091-A | Triazine mercapto derivate as well as preparation method and application thereof | UNIV SHANDONG | 2012-12-19 | — | — | CN | claimed |
| EP-2480529-A1 | INDOLE DERIVATIVES AS CRAC MODULATORS | F. Hoffmann-La Roche AG (CH) | 2012-08-01 | — | — | EP | claimed |
| CN-102574788-A | Indole derivatives as crac modulators | HOFFMANN LA ROCHE | 2012-07-11 | — | — | CN | claimed |
| CN-102276535-A | Azazine mercaptoacetamide derivative and preparation method and application thereof | — | 2011-12-14 | — | — | CN | claimed |
| WO-2011036130-A1 | INDOLE DERIVATIVES AS CRAC MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-31 | — | — | WO | claimed |
| US-20110071150-A1 | INDOLE DERIVATIVES AS CRAC MODULATORS | ALAM MUZAFFAR | 2011-03-24 | — | — | US | claimed |
| WO-2005115147-A2 | HIV REVERSE TRANSCRIPTASE INHIBITORS | MERCK & CO., INC. (US) | 2005-12-08 | — | — | WO | claimed |
| US-20050239853-A1 | New compounds | BIOVITRUM AB (SE) | 2005-10-27 | — | — | US | claimed |
| WO-2005075471-A2 | THIAZOL-COMPOUNDS AS 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS | BIOVITRUM AB (SE) | 2005-08-18 | — | — | WO | claimed |
| EP-0031708-B1 | CEPHALOSPORIN DERIVATIVES, PROCESSES FOR THEIR MANUFACTURE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND INTERMEDIATES THEREFOR | ICI PHARMA (FR) | 1984-06-13 | — | — | EP | claimed |
| EP-0031708-A2 | Cephalosporin derivatives, processes for their manufacture, pharmaceutical compositions containing them and intermediates therefor | ICI PHARMA (FR) | 1981-07-08 | — | — | EP | claimed |
| CN-113767105-A | Heterocyclic compounds as inhibitors of monoacylglycerol lipases (MAGL) | 豪夫迈·罗氏有限公司 | 2021-12-07 | — | — | CN | disclosed |
| CN-110312724-A | SUBSTITUTED THIAZOLO-PYRIDINE COMPOUNDS AS MALT1 INHIBITORS | 陆品有限公司 | 2019-10-08 | — | — | CN | disclosed |
| CN-108299420-A | Five cyclics alternatively adjusted under property estrogen receptor and its application | 南京圣和药业股份有限公司 | 2018-07-20 | — | — | CN | disclosed |
| CN-107207488-A | It is used as the bicyclic heteroaryl heteroaryl benzoic acid compounds of retinoic acid receptors β (RAR β) activator | 伦敦皇家学院 | 2017-09-26 | — | — | CN | disclosed |
| US-4914117-A | ANTIDEPRESSANTS, CENTRAL NERVOUS SYSTEM ACTIVATORS; DOPAMINE ANTAGONISTS | SOCIETE D'ETUDES SCIENTIFIQUES ET INDUSTRIELLE DE L'ILE-D-FRANCE (FR) | 1990-04-03 | — | — | US | disclosed |
| CN-86108972-A | New benzamides and preparation method thereof and the application in treatment | — | 1987-11-18 | — | — | CN | disclosed |
| US-4463173-A | ANTIBIOTIC, BACTERICIDE | ICI PHARMA (FR) | 1984-07-31 | — | — | US | disclosed |
| EP-0031708-B1 | CEPHALOSPORIN DERIVATIVES, PROCESSES FOR THEIR MANUFACTURE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND INTERMEDIATES THEREFOR | ICI PHARMA (FR) | 1984-06-13 | — | — | EP | disclosed |
| EP-0031708-A2 | Cephalosporin derivatives, processes for their manufacture, pharmaceutical compositions containing them and intermediates therefor | ICI PHARMA (FR) | 1981-07-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239853-A1 | New compounds | HSD11B1, CYP11B1, HSD3B1 | CA1 1669/4885CA2 2138/4885CA12 2476/4885 |
| US-20110071150-A1 | INDOLE DERIVATIVES AS CRAC MODULATORS | ORAI1, RYR2, CACNA1E | CA1 690/4885CA2 100/4885CA12 3008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.